GSK Blood Cancer Drug Issues

News

GSK, FDA and Drug Administration

FDA advisers say risks of GSK blood cancer drug outweigh benefits in surprise setback

FDA advisers on Thursday voted against GSK's blood cancer drug Blenrep, finding that its risks outweighed its benefits at the selected dose

Reuters on MSN · 2d

GSK falls as blood cancer drug likely headed for US rejection

(Reuters) -GSK shares fell more than 6% on Friday to the bottom of Britain's blue-chip index after a U.S. FDA advisory panel recommended against approving its blood cancer drug Blenrep, citing earlier concerns over side effects.

AOL · 2d

GSK's Blood Cancer Drug Faces US Setback Due To FDA Panel's Eye Safety Warning

Oncologic Drugs Advisory Committee (ODAC) voted against the overall benefit/risk profile at the proposed dosage of GSK plc’s (NYSE:GSK) Blenrep (belantamab mafodotin-blmf) combinations. The belantamab mafodotin combinations were evaluated in adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.

STAT2d

Pharmalittle: We’re reading about a GSK setback, another Sarepta gene therapy death, and more

In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...

Bloomberg L.P.1y

GSK’s Withdrawn Blood Cancer Drug Poised for Comeback

GSK Plc said a blood cancer drug it had to pull from the market after a trial failure has shown promising results when combined with another cancer treatment. Skip to content.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

News

GSK, FDA and Drug Administration

Trending now